Skip to main content
Aura Biosciences, Inc. logo

Aura Biosciences, Inc. — Investor Relations & Filings

Ticker · AURA ISIN · US05153U1079 US Manufacturing
Open in API
Filings indexed 323 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country US United States of America
Listing US AURA

About Aura Biosciences, Inc.

https://aurabiosciences.com/

Aura Biosciences is a clinical-stage biotechnology company developing a new class of targeted therapies for solid tumors. The company's proprietary platform creates Virus-Like Drug Conjugates (VDCs), which use Virus-Like Particles to selectively deliver anti-cancer agents to tumor cells. This approach is designed to destroy cancer while preserving healthy tissue and organ function. Aura's initial focus is on ocular and urologic oncology, with a lead program for the first-line treatment of choroidal melanoma, a rare, vision-threatening eye cancer that lacks approved drug therapies. The company aims to establish a new standard of care across multiple cancer indications.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 90% confidence The document is a Form S-8 Registration Statement filed with the U.S. SEC, registering shares of common stock for employee inducement awards. It is not an annual report, proxy, earnings release, or management change notice, but rather a regulatory filing to authorize new share issuance under equity plans. Under the filing definitions, this constitutes a capital change/share issuance announcement. Therefore, it is classified as a Share Issue/Capital Change (SHA).
2026-05-19 English
424B5 - Aura Biosciences, Inc. (0001501796) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a Form 424B5 preliminary prospectus supplement and accompanying shelf prospectus for an offering of common stock and pre-funded warrants under an S-3 registration. It provides the detailed terms of the equity raising, underwriting arrangements, use of proceeds and related legal and risk disclosures. This is not an earnings release, financial report, proxy, or management report; it is a financing document associated with a new share issuance. Under the taxonomy, such fundraising and capital structure updates fall under Capital/Financing Update (CAP).
2026-05-04 English
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
Board/Management Information Classification · 93% confidence The document is an SEC Form 8-K current report (reported under Items 5.02) that details the appointment of a new Chief Executive Officer and President, the departure of the previous CEO, and related compensatory and equity arrangements. This is an announcement of changes in senior management, fitting the ‘Board/Management Information’ category.
2026-05-04 English
ARS - Aura Biosciences, Inc. (0001501796) (Filer)
Annual Report
2026-04-20 English
S-8 - Aura Biosciences, Inc. (0001501796) (Filer)
Share Issue/Capital Change Classification · 95% confidence The document is a Form S-8 registration fee calculation exhibit related to the registration of securities under employee stock plans. It details the number of shares registered, the offering price, and the registration fee calculation. This type of filing is related to share issuance and capital changes, specifically the registration of new shares for employee stock plans. It is not a financial report, earnings release, or management discussion. The document is short (3597 characters) and focused on registration fee calculation for securities issuance. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2026-03-30 English
10-K - Aura Biosciences, Inc. (0001501796) (Filer)
Annual Report FY 2025
2026-03-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.